<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21400" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Etoposide</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Reyhanoglu</surname>
            <given-names>Gizem</given-names>
          </name>
          <aff>LECOM</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tadi</surname>
            <given-names>Prasanna</given-names>
          </name>
          <aff>Asram Medical College, Eluru, India</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Gizem Reyhanoglu declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Prasanna Tadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>4</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21400.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Etoposide is a medication used in the management and treatment of various cancers such as testicular, prostate, bladder, stomach, and lung cancer. It is in the topoisomerase II inhibitor class of medications. This activity outlines the indications, action, and contraindications for etoposide as a valuable agent in managing various cancers listed above, Hodgkin and non-Hodgkin lymphoma and brain tumors. (and other disorders when applicable). This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the healthcare team in the treatment of patients with various cancers, lymphomas, leukemias, and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the common indications for the use of etoposide.</p></list-item><list-item><p>Describe the typical adverse effects of etoposide.</p></list-item><list-item><p>Review the risk factors for developing toxicity with etoposide.</p></list-item><list-item><p>Summarize the importance of improving care coordination amongst the interprofessional team to enhance care coordination for patients receiving etoposide chemotherapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21400&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21400">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21400.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Etoposide, a topoisomerase II inhibitor, was first synthesized in 1966 and then approved in 1983 by the United States Food and Drug Administration (FDA) for cancer therapy.<xref ref-type="bibr" rid="article-21400.r1">[1]</xref>&#x000a0;It is a semi-synthetic compound derived from the North American mayapple, <italic toggle="yes">Podophyllum peltatum</italic>, and the Indian species&#x000a0;<italic toggle="yes">Podophyllum emodi</italic>.<xref ref-type="bibr" rid="article-21400.r2">[2]</xref></p>
        <p>Etoposide has proven effective when administered through multiple dosings over three to five consecutive days rather than a single weekly dose.<xref ref-type="bibr" rid="article-21400.r2">[2]</xref>&#x000a0;It is currently FDA-approved for small cell lung cancer (SCLC) and testicular cancer. Research has observed it to have high single-agent activity against SCLC.<xref ref-type="bibr" rid="article-21400.r3">[3]</xref>&#x000a0;It can be combined with carboplatin against SCLC as well.<xref ref-type="bibr" rid="article-21400.r4">[4]</xref>&#x000a0;The carboplatin/etoposide combination has&#x000a0;demonstrated a better toxicity profile compared to cisplatin/etoposide and is much better tolerated in the elderly population.<xref ref-type="bibr" rid="article-21400.r4">[4]</xref>&#x000a0;When using etoposide in combination with other chemotherapeutic agents against testicular cancer, response rates of about 80% have been observed in patients.<xref ref-type="bibr" rid="article-21400.r5">[5]</xref>&#x000a0;Recent clinical studies are beginning to observe the use of etoposide as an agent for initial therapy and the efficacy of using etoposide in higher doses and prolonged schedules.<xref ref-type="bibr" rid="article-21400.r6">[6]</xref></p>
        <p>Etoposide is also one of the most active chemotherapeutic drugs for other cancers, such as refractory pediatric neoplasms, hepatocellular carcinomas, acute nonlymphocytic leukemia (ANLL), prostatic carcinomas, ovarian carcinomas, and non-small cell lung cancer.<xref ref-type="bibr" rid="article-21400.r2">[2]</xref></p>
        <p>Etoposide is inactive against malignant melanoma, colorectal cancer, and cancer of the head and neck.<xref ref-type="bibr" rid="article-21400.r2">[2]</xref></p>
      </sec>
      <sec id="article-21400.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Etoposide is a topoisomerase II inhibitor. Its mechanism of action is primarily in the late S and G2 phases of the cell cycle.<xref ref-type="bibr" rid="article-21400.r2">[2]</xref>&#x000a0;Topoisomerase II is cut both strands of the DNA helix simultaneously.&#x000a0;It creates and reseals double-stranded DNA breaks during the replication process.<xref ref-type="bibr" rid="article-21400.r7">[7]</xref>&#x000a0;Etoposide poisons the topoisomerase II cleavage complexes and inhibiting the second step of the reaction, DNA re-ligation.<xref ref-type="bibr" rid="article-21400.r7">[7]</xref><xref ref-type="bibr" rid="article-21400.r1">[1]</xref>&#x000a0;The etoposide-topoisomerase II complex triggers a mutagenic and cell death pathway, working best in tumor cells with higher levels of topoisomerase II enzymes.<xref ref-type="bibr" rid="article-21400.r8">[8]</xref></p>
      </sec>
      <sec id="article-21400.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Etoposide is available as an oral or IV preparation chemotherapy agent.<xref ref-type="bibr" rid="article-21400.r9">[9]</xref>&#x000a0;Its formulation is etoposide phosphate, a water-soluble prodrug that rapidly converts into its active form.<xref ref-type="bibr" rid="article-21400.r10">[10]</xref>&#x000a0;Etoposide has a wide distribution in the body and is highly bound to plasma proteins.<xref ref-type="bibr" rid="article-21400.r5">[5]</xref>&#x000a0;Therapy regimens vary depending on the type of tumor or malignancy treated, as etoposide's effects are strongly schedule-dependent.<xref ref-type="bibr" rid="article-21400.r9">[9]</xref>&#x000a0;The efficacy of the chemotherapeutic agent depends on both the dose and time of exposure.<xref ref-type="bibr" rid="article-21400.r6">[6]</xref>&#x000a0;Daily 30-minute infusion for five days of 100 mg/m^2 is considered a tolerable dose before patients are affected by the dose-limiting side effects such as myelosuppression.<xref ref-type="bibr" rid="article-21400.r10">[10]</xref>&#x000a0;If given intravenously, the administration of the drug must be given in slowly over a 30 to 60 minute period, as there have been studies showing a decrease in blood pressure during administration. Blood pressure requires monitoring during etoposide administration.</p>
        <p>Common dosing regimens for approved indications include:</p>
        <list list-type="bullet">
          <list-item>
            <p>For refractory testicular cancer
<list list-type="bullet"><list-item><p>50 to 100 mg/m^2 per daily single dose on days 1 through 5 of a 21-day cycle. Alternately, dosing can be 100 mg/m^2 daily on days 1, 3, and 5 of a 21-day cycle.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>For small cell lung cancer:
<list list-type="bullet"><list-item><p>Oral dosing: 70 mg/m^2 orally each day for&#x000a0;the first&#x000a0;4 days, up to 100 mg/m^2 orally for the first 5 days of a 21&#x000a0;or 28-day cycle.</p></list-item><list-item><p>IV dosing: 35 mg/m^2 IV for the first 4 days, up to 50 mg/m^2 for the first 5 days&#x000a0;of a&#x000a0;21 or 28-day cycle.</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Renal dosing adjustments: for CrCl of 15 to 50, decrease the typical dose 25%, CrCl under 15 cut dose by 50%. For peritoneal or hemodialysis patients, cut the dose by 50%.</p>
        <p>As part of the bleomycin, etoposide, cisplatin (BEP) therapy, etoposide has been proven effective for metastatic non-seminomatous testicular cancer and malignant ovarian germ cell tumors.<xref ref-type="bibr" rid="article-21400.r11">[11]</xref><xref ref-type="bibr" rid="article-21400.r12">[12]</xref></p>
      </sec>
      <sec id="article-21400.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Etoposide is a relatively well-tolerated chemotherapeutic agent.<xref ref-type="bibr" rid="article-21400.r7">[7]</xref>&#x000a0;Common adverse effects include alopecia and gastrointestinal toxicity. GI toxicity includes nausea, vomiting, and stomatitis.<xref ref-type="bibr" rid="article-21400.r2">[2]</xref>&#x000a0;The GI toxicity is relatively mild compared to other antineoplastic medications and can be well controlled with antiemetic therapy.&#x000a0;Alopecia is commonly observed at standard doses and becomes a universal side effect at doses of 500 mg/m^2 or higher.&#x000a0;The dose-limiting side effect of etoposide is myelosuppression.<xref ref-type="bibr" rid="article-21400.r7">[7]</xref></p>
        <p>Although the mechanism is unknown, acute hypersensitivity reactions can occur with the use of etoposide.&#x000a0;During intravenous administration, patients can experience flushing, bronchospasm, cyanosis, hypertension, or hypotension.<xref ref-type="bibr" rid="article-21400.r7">[7]</xref>&#x000a0;Hypersensitivity reaction symptoms resolve within minutes after discontinuing the intravenous administration of etoposide. Once a patient has experienced a hypersensitivity reaction, it is possible to readminister the drug safely with premedication with corticosteroids and antihistamines.<xref ref-type="bibr" rid="article-21400.r7">[7]</xref>&#x000a0;</p>
        <p>Patients on warfarin require close monitoring when using etoposide because of the potential side effects of bleeding.<xref ref-type="bibr" rid="article-21400.r13">[13]</xref></p>
        <p>Different mechanisms have noted resistance to etoposide.&#x000a0;Those cells with low levels of topoisomerase II are resistant to etoposide.&#x000a0;The multiple drug resistance efflux pump also removes etoposide from cells.&#x000a0;Some malignant cells have even deactivated etoposide.<xref ref-type="bibr" rid="article-21400.r7">[7]</xref></p>
      </sec>
      <sec id="article-21400.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Etoposide is relatively contraindicated during breastfeeding.<xref ref-type="bibr" rid="article-21400.r14">[14]</xref>&#x000a0;Breastfeeding can resume after at least 24 hours after 80 mg/m^2 or less dosage of etoposide. This limitation is because it appears that chemotherapy can alter the normal microbiome and chemical make-up of breastmilk, adversely limiting the nutrients necessary for proper development in a baby.<xref ref-type="bibr" rid="article-21400.r14">[14]</xref></p>
      </sec>
      <sec id="article-21400.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>While administering etoposide, the healthcare team members must consider the different factors that could affect a patient's side effect profile. There was a noted correlation between age and leukopenia/neutropenia risk in patients with normal organ function.&#x000a0;An increase in age was also associated with a decrease in drug clearance, as well as an increase in drug AUC.<xref ref-type="bibr" rid="article-21400.r3">[3]</xref></p>
        <p>Patients with low serum albumin concentrations may have worsening hematological adverse reactions. Patients with normal albumin levels that had elevated liver enzyme levels could demonstrate an increase in the incidence of neutropenia.<xref ref-type="bibr" rid="article-21400.r3">[3]</xref></p>
      </sec>
      <sec id="article-21400.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Myelosuppression is the dose-limiting toxicity of etoposide.<xref ref-type="bibr" rid="article-21400.r2">[2]</xref>&#x000a0;Research data showed alopecia, nausea, vomiting, and stomatitis&#x000a0;occurring in 20&#x000a0;to 30% of patients.<xref ref-type="bibr" rid="article-21400.r2">[2]</xref></p>
        <p>It can also be involved in drug-induced secondary malignancies, such as acute myelocytic leukemia (t-AML).<xref ref-type="bibr" rid="article-21400.r1">[1]</xref>&#x000a0;Etoposide-induced t-AML is associated with the translocation on chromosome 11q23.<xref ref-type="bibr" rid="article-21400.r1">[1]</xref></p>
      </sec>
      <sec id="article-21400.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Etoposide is a strong chemotherapeutic agent that has a proven record of working against various human malignancies. As the drug's list of expanding clinical uses grows, the healthcare teams should find strategies to improve its administration and effectiveness for patients.</p>
        <p>Additional research is necessary to consider etoposide as initial therapy in several cancers.<xref ref-type="bibr" rid="article-21400.r6">[6]</xref>&#x000a0;Etoposide has already shown therapeutic activity against testicular cancer, small cell carcinoma of the lung, leukemias, lymphomas, and more. As initial therapy, etoposide can potentially reduce the administration of multiple chemotherapeutic agents and thus, reduce side effect profiles for patients undergoing treatment.&#x000a0;</p>
        <p>As research has shown, etoposide is a potent chemotherapeutic agent that is schedule-dependent.<xref ref-type="bibr" rid="article-21400.r9">[9]</xref> The dosing and timing of etoposide make a difference in how effective it is. New research should lean toward considering etoposide against cancers at higher doses and prolonged scheduling.<xref ref-type="bibr" rid="article-21400.r6">[6]</xref>&#x000a0;The interprofessional healthcare team should engage the services of an oncology specialized pharmacist to optimize the regimen for maximum therapeutic effect while minimizing adverse effects. [Level 5]</p>
      </sec>
      <sec id="article-21400.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21400&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21400">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21400/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21400">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-21400.s11">
        <title>References</title>
        <ref id="article-21400.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Montecucco</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zanetta</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Biamonti</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Molecular mechanisms of etoposide.</article-title>
            <source>EXCLI J</source>
            <year>2015</year>
            <volume>14</volume>
            <fpage>95</fpage>
            <page-range>95-108</page-range>
            <pub-id pub-id-type="pmid">26600742</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21400.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sinkule</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Etoposide: a semisynthetic epipodophyllotoxin. Chemistry, pharmacology, pharmacokinetics, adverse effects and use as an antineoplastic agent.</article-title>
            <source>Pharmacotherapy</source>
            <year>1984</year>
            <season>Mar-Apr</season>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>61</fpage>
            <page-range>61-73</page-range>
            <pub-id pub-id-type="pmid">6326063</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21400.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Joel</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Slevin</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Etoposide dosage and pharmacodynamics.</article-title>
            <source>Cancer Chemother Pharmacol</source>
            <year>1994</year>
            <volume>34 Suppl</volume>
            <fpage>S69</fpage>
            <page-range>S69-75</page-range>
            <pub-id pub-id-type="pmid">8070031</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21400.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bishop</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Carboplatin/etoposide in small cell lung cancer.</article-title>
            <source>Oncology</source>
            <year>1992</year>
            <volume>49 Suppl 1</volume>
            <fpage>11</fpage>
            <page-range>11-7; discussion 17-8</page-range>
            <pub-id pub-id-type="pmid">1323807</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21400.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fleming</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>CF</given-names>
              </name>
            </person-group>
            <article-title>Etoposide: an update.</article-title>
            <source>Clin Pharm</source>
            <year>1989</year>
            <month>Apr</month>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>274</fpage>
            <page-range>274-93</page-range>
            <pub-id pub-id-type="pmid">2653712</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21400.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aisner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Etoposide. Current and future status.</article-title>
            <source>Cancer</source>
            <year>1991</year>
            <month>Jan</month>
            <day>01</day>
            <volume>67</volume>
            <issue>1 Suppl</issue>
            <fpage>215</fpage>
            <page-range>215-9</page-range>
            <pub-id pub-id-type="pmid">1984822</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21400.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hainsworth</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Greco</surname>
                <given-names>FA</given-names>
              </name>
            </person-group>
            <article-title>Etoposide: twenty years later.</article-title>
            <source>Ann Oncol</source>
            <year>1995</year>
            <month>Apr</month>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>325</fpage>
            <page-range>325-41</page-range>
            <pub-id pub-id-type="pmid">7619747</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21400.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meresse</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dechaux</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Monneret</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bertounesque</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Etoposide: discovery and medicinal chemistry.</article-title>
            <source>Curr Med Chem</source>
            <year>2004</year>
            <month>Sep</month>
            <volume>11</volume>
            <issue>18</issue>
            <fpage>2443</fpage>
            <page-range>2443-66</page-range>
            <pub-id pub-id-type="pmid">15379707</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21400.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carney</surname>
                <given-names>DN</given-names>
              </name>
            </person-group>
            <article-title>The pharmacology of intravenous and oral etoposide.</article-title>
            <source>Cancer</source>
            <year>1991</year>
            <month>Jan</month>
            <day>01</day>
            <volume>67</volume>
            <issue>1 Suppl</issue>
            <fpage>299</fpage>
            <page-range>299-302</page-range>
            <pub-id pub-id-type="pmid">1984831</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21400.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thompson</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Greco</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Srinivas</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Igwenezue</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Hainsworth</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Schacter</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Kaul</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Barbhaiya</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Garrow</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>A phase I study of etoposide phosphate administered as a daily 30-minute infusion for 5 days.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>1995</year>
            <month>May</month>
            <volume>57</volume>
            <issue>5</issue>
            <fpage>499</fpage>
            <page-range>499-507</page-range>
            <pub-id pub-id-type="pmid">7768072</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21400.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Wit</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Stoter</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Sleijfer</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>ten Bokkel Huinink</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Rea</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Collette</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sylvester</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group.</article-title>
            <source>J Clin Oncol</source>
            <year>1997</year>
            <month>May</month>
            <volume>15</volume>
            <issue>5</issue>
            <fpage>1837</fpage>
            <page-range>1837-43</page-range>
            <pub-id pub-id-type="pmid">9164193</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21400.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Weng</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Wen</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Chou</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>YF</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Chou</surname>
                <given-names>CY</given-names>
              </name>
            </person-group>
            <article-title>Outcome of 3-day bleomycin, etoposide and cisplatin chemotherapeutic regimen for patients with malignant ovarian germ cell tumours: a Taiwanese Gynecologic Oncology Group study.</article-title>
            <source>Eur J Cancer</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>50</volume>
            <issue>18</issue>
            <fpage>3161</fpage>
            <page-range>3161-7</page-range>
            <pub-id pub-id-type="pmid">25459394</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21400.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hande</surname>
                <given-names>KR</given-names>
              </name>
            </person-group>
            <article-title>Etoposide: four decades of development of a topoisomerase II inhibitor.</article-title>
            <source>Eur J Cancer</source>
            <year>1998</year>
            <month>Sep</month>
            <volume>34</volume>
            <issue>10</issue>
            <fpage>1514</fpage>
            <page-range>1514-21</page-range>
            <pub-id pub-id-type="pmid">9893622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21400.r14">
          <label>14</label>
          <element-citation publication-type="book">
            <chapter-title>Etoposide</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>1</month>
            <day>18</day>
            <pub-id pub-id-type="pmid">29999703</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
